Sign inJoin waitlistJoin the waitlist

Adedayo Onitilo

Clinical Associate Professor, Department of Medicine-University of Wisconsin School of Medicine and Public Health, Madison, WI · Marshfield Clinic

Credentials: · · · · ·

History

Marshfield Clinic
Present
University of Wisconsin Hospitals and Clinics
Present
University of Wisconsin Hospitals and Clinics
Present

Hematology and Medical Oncology
1998–2001
Internal Medicine
Harlem Hospital Center
1995–1998
Medical University of South Carolina
Ogun State University, Sagamu, Nigeria
1991–1995

Research

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
New England Journal of Medicine · 2023 · 739 citations
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival
Clinical Medicine & Research · 2009 · First of 4 authors · Corresponding · 639 citations
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study
Journal of the National Cancer Institute · 2012 · 450 citations

Jessica Engel
50 papers
Elizabeth Burnside
9 papers
Sabo Tanimu
9 papers
Supriya Mohile
8 papers
Michael Sheehan
7 papers
OB
Onyinye Balogun
6 papers · 2 as a resident
Kah Loh
5 papers · 1 as a fellow
Kari Wisinski
5 papers
Keith Flaherty
5 papers
Laurence McCahill
5 papers
Mark Burkard
5 papers
Ted James
5 papers

Grants

Wisconsin NCI Community Oncology Research Program (WiNCORP)
National Cancer Institute · UG1
Contact PI · $29.6M · Marshfield Clinic, Inc.
2014–2027

Clinical trials

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2025–2028
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2024–2028